The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-More bad news for luxury

Thu, 29th Oct 2020 10:20

Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

MORE BAD NEWS FOR LUXURY (1020 GMT)

Nobody likes restrictive measures but luxury will probably
be one of the hardest hit industries after France said it would
go back to a nationwide lockdown.

“The impact of store closures in France, one of the biggest
luxury goods markets in the region, in the important Q4, and
looming risk of further closures across the continent is going
to result in negative earnings revisions for the companies in
our coverage,” a UBS research note says.

The new measures in France, which will last until Dec. 1,
will mean people have to stay in their homes except to buy
essential goods, seek medical attention, or use their daily
one-hour allocation of exercise.

(Stefano Rebaudo)

*****

EUROPE OPENS HIGHER AS TECH SHINES (0848 GMT)

European stocks manage to keep their head above water as of
now, after yesterday’s brutal selloff as focus turns to an ECB
policy meeting which might give some clues about fresh stimulus.

Tech stocks are among the best performers, despite a double
digit fall in Nokia shares, ahead of results in the
from Apple, Alphabet, Facebook and Twitter.

The Stoxx 600 index is up 0.3%, with real estate
sector leading gains up 1.1% and tech stocks up 1%. Insurers and
travel and leisure stocks are down about 0.6%.

Shares in Orange are up 5.1% after results, while
BT +7% after the company raises the lower end of its
earnings outlook for the year.

Royal Dutch Shell shares rise 3.8% after the
company said it will increase its third-quarter dividend by 4%
and reported stronger-than-expected profits.

(Stefano Rebaudo)

*****

ON THE RADAR: SHELL, AB INBEV, AIRBUS, NOKIA (0733 GMT)

European stocks are attempting to open slightly higher a day
after the biggest fall in months and hours ahead of an ECB
policy meeting.

Meanwhile senior sources in the British government expect
the vaccine, which Pfizer is co-developing with Germany's
BioNTech, could be ready to distribute before
Christmas, the Times reports. A verdict on this vaccine will be
available before the results are in on AstraZeneca Plc's
competing vaccine, it adds.

On the corporate front, a batch of good results is on its
way, with Nokia reporting third-quarter underlying
profit in line with market expectations.

Royal Dutch Shell will increase its third-quarter
dividend by 4% after stronger-than-expected profits in the
quarter.

Anheuser-Busch InBev reports a surprise increase in
beer sales in the third quarter, although profits dip and its
interim dividend payment is scrapped due to the COVID-19
pandemic.

Airbus expects to reach cash breakeven in the
fourth quarter, setting the first forward-looking target since
the start of the coronavirus crisis, after posting revenues of
11.2 billion euros versus analysts’ expectations of 11.4
billion.

Shares in Fresenius are up 2.3% in premarket trade
after the company’s third-quarter net income beats expectations.

Orange posts a 0.4% decline in its third-quarter
core operating profit, beating market expectations.

Telefonica expects a return to revenue growth in
2022 after a 785 million euro impairment charge in Argentina
dragged it to a net loss in the third quarter.

Volkswagen shares are up 1.8% in premarket trade
after the company returned to profitability in the third
quarter.

Roche shares are up 2.5% in premarket trade after
Chinese approval of Tecentriq.

Credit Suisse Group is seen down 1% after the bank
posts a 546 million Swiss francs in July-September, which is
compared with the 572 million franc median of 17 analyst
estimates compiled by the lender.

Standard Chartered booked a smaller-than-expected
40% slide in quarterly profit as the lender lowered its loan
loss expectations, also saying client demand was likely to
increase next year.

U.S. jeweller Tiffany & Co agreed with LVMH
to slightly lower the price of its acquisition by the
French luxury goods group, in a move set to end a legal dispute
between the two.

(Stefano Rebaudo)

*****

EUROPEAN STOCKS POISED FOR A REBOUND (0633 GMT)

European stock futures are in positive territory after
yesterday’s biggest fall in months on fears about the economic
impact of new restrictive measures across Europe.

Equities seem ready for a rebound ahead of an ECB policy
meeting scheduled for today which might give some clues about a
possible new round of economic stimulus.

German unemployment and inflation data, European confidence
surveys will also be closely watched, while uncertainty about
U.S. presidential elections and coronavirus worries continue to
keep investors on edge.

(Stefano Rebaudo)

*****

More News
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.